To include your compound in the COVID-19 Resource Center, submit it here.

How to open your mouth

The financing needs of the biotech industry leave it particularly vulnerable to securities fraud claims, as companies with no products or earnings seek the attention of Wall Street through projections of future events.

As Larry Sonsini, chairman of Wilson Sonsini Goodrich & Rosati, told a San Francisco seminar last week, the

Read the full 506 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers